Overview

AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer

Status:
Completed

Trial end date:
2010-05-11

Target enrollment:

Participant gender:

Summary

This study will evaluate AMG 162 in the treatment of bone loss in subjects undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer.

Phase:

Phase 3

Details

Lead Sponsor:

Amgen

Treatments:

Androgens
Denosumab